levodopa has been researched along with ascorbic acid in 75 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (18.67) | 18.7374 |
| 1990's | 18 (24.00) | 18.2507 |
| 2000's | 20 (26.67) | 29.6817 |
| 2010's | 21 (28.00) | 24.3611 |
| 2020's | 2 (2.67) | 2.80 |
| Authors | Studies |
|---|---|
| Kubo, I; Nihei, Ki | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Avgoustakis, K; Bariamis, SE; Drainas, D; Hadjipavlou-Litina, D; Magoulas, GE; Papaioannou, D | 1 |
| Sacks, W; Simpson, GM | 1 |
| Atkinson, AR; Norris, KA; Smith, WG | 1 |
| Abroms, IF; Breslow, JL; Brewster, TG; Kaufman, S; Milstien, S; Moskowitz, MA | 1 |
| Henocque, G; Koffi, A; Macart, M | 1 |
| Dettman, G | 1 |
| Abdallah, RM; Meadows, GG; Pierson, HF | 1 |
| Fahn, S | 1 |
| Benedetti, MS; Dostert, P; Frigerio, E | 1 |
| Chattopadhyay, S; Das, A | 1 |
| Palleschi, A; Paradossi, G; Pispisa, B | 1 |
| Galindo, JD; Peñafiel, R; Solano-Muñoz, F | 1 |
| Ervin, GN; Nemeroff, CB | 1 |
| Abdallah, RM; Meadows, GG; Starkey, JR | 1 |
| Meadows, GG; Pierson, HF | 2 |
| Colombo, JP; Küffer, H; Peheim, E; Richterich, R | 1 |
| Hershey, L; Reilly, DK; Rivera-Calimlim, L; Shoulson, I | 1 |
| Arese, P; Sisini, A; Spanu, A | 1 |
| Cohen, G; Li, CL; Werner, P | 1 |
| Fahn, S; Jackson-Lewis, V; Przedborski, S | 1 |
| López Lozano, JJ; Moreno Cano, R | 1 |
| Cohen, G; Mytilineou, C; Werner, P; Yahr, MD | 1 |
| de Yébenes, JG; Mena, MA; Pardo, B | 1 |
| Cohen, G | 1 |
| Balaraman, K; Hoti, SL | 1 |
| Fahn, S; García de Yébenes, J; Mena, MA; Pardo, B | 1 |
| De Yebenes, JG; Mena, MA; Paino, CL; Pardo, B | 1 |
| Buhrfiend, C; Carvey, PM; Goetz, CG; Lipton, JW; Pappert, EJ; Stebbins, GT | 1 |
| Akaike, A; Cheng, N; Goshima, Y; Kaneko, S; Kochiyama, H; Kume, T; Maeda, T; Misu, Y | 1 |
| Lai, CT; Yu, PH | 1 |
| Jiménez-Jiménez, FJ; Molina, JA | 1 |
| De Natale, G; Delogu, MR; Desole, MS; Godani, C; Miele, E; Migheli, R; Sciola, L; Serra, PA; Zangani, D | 1 |
| Asanuma, M; Furuta, H; Miyazaki, I; Ogawa, N; Sogawa, CA; Sogawa, N | 1 |
| Alves, TL; Carvalho, GM; Freire, DM | 1 |
| Delogu, MR; Desole, MS; Enrico, P; Esposito, G; Grella, G; Miele, E; Miele, M; Migheli, R; Mura, MA; Serra, PA | 1 |
| Beauregard, M; Chapados, C; Gélinas, S; Gosselin, I; Martinoli, MG | 1 |
| Szakács, T; Vereczkey, L; Veres, Z | 1 |
| Canals, S; Casarejos, MJ; de Bernardo, S; Handler, A; Mena, MA; Rodríguez-Martín, E | 1 |
| Castell, A; Corona-Morales, AA; Drucker-Colín, R; Escobar, A; Zhang, L | 1 |
| Homma, T; Kanehira, T; Nagata, H; Osamura, RY; Takekoshi, S | 1 |
| Arlt, S; Beisiegel, U; Buhmann, C; Kontush, A; Möller-Bertram, T; Oechsner, M; Sperber, S; Stuerenburg, HJ | 1 |
| Hachinohe, M; Matsumoto, H | 1 |
| Johirul, M; Kim, RE; Shiddiky, A; Shim, YB | 1 |
| Daya, S; Maharaj, H; Mokokong, R; Scheepers, M; Sukhdev Maharaj, D | 1 |
| Karpińska, J; Smyk, J; Wołyniec, E | 1 |
| Desole, MS; Esposito, G; Marchetti, B; Miele, E; Migheli, R; Rocchitta, G; Serra, PA | 1 |
| Quach, HT; Smith, WE; Vatassery, GT | 1 |
| John, SA; Sivanesan, A | 1 |
| Bhide, PG; Lueras, P; McCarthy, D | 1 |
| Borah, A; Mohanakumar, KP | 1 |
| Ali, S; Mariam, I; Rehman, A | 1 |
| Jadhav, JP; Surwase, SN | 1 |
| Fan, T; Fan, X; Jiang, G; Jing, Z; Yu, M | 1 |
| Kabuto, H; Yamanushi, TT | 1 |
| Apine, OA; Jadhav, JP; Patil, SA; Surwase, SN | 1 |
| Afzal, M; Jyoti, S; Khan, S; Naz, F; Shakya, B; Siddique, YH | 1 |
| Ballaz, S; Fuentes, A; Morales, I; Obeso, JA; Rodriguez, M | 1 |
| Baltas, N; Can, Z; Dincer, B; Kolayli, S; Sahin, H; Yildiz, O | 1 |
| Dolan, RJ; McNab, F | 1 |
| Stansley, BJ; Yamamoto, BK | 1 |
| Bryjak, J; Cieńska, M; Koźlecki, T; Labus, K; Lewańczuk, M; Liesiene, J | 1 |
| Ahmadouk, NA; Gopaluni, S; Sherif, M | 1 |
| Ehm, G; Jeon, B; Kim, A; Kim, HJ; Kim, YE; Lee, WW; Yang, HJ; Yun, JY | 1 |
| Cózar-Bernal, MJ; García Esteban, E; González-Rodríguez, ML; Rabasco Álvarez, AM | 1 |
| Dhanalakshmi, N; Karthikeyan, V; Priya, T; Thinakaran, N | 1 |
| Kubo, M; Miyaue, N; Nagai, M | 1 |
| Allegritti, E; Battista, S; Galantini, L; Giansanti, L; Maggi, MA; Marconi, C | 1 |
3 review(s) available for levodopa and ascorbic acid
| Article | Year |
|---|---|
Enzymatic/nonenzymatic sources of oxyradicals and regulation of antioxidant defenses.
Topics: Animals; Antioxidants; Ascorbic Acid; Enzymes; Escherichia coli; Free Radicals; Glutathione; Humans; Hydrogen Peroxide; Hydroxyl Radical; Levodopa; Mesencephalon; Neurons; Paraquat; Peroxides; Reactive Oxygen Species; Superoxides | 1994 |
[Pharmacological therapy of complicated Parkinson's disease].
Topics: Antiparkinson Agents; Ascorbic Acid; Combined Modality Therapy; Diet Therapy; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Humans; Levodopa; Parkinson Disease | 1997 |
Interventions for chronic kidney disease-associated restless legs syndrome.
Topics: Amines; Anticonvulsants; Ascorbic Acid; Cyclohexanecarboxylic Acids; Dopamine Agonists; Exercise Therapy; Gabapentin; gamma-Aminobutyric Acid; Humans; Indoles; Iron-Dextran Complex; Levodopa; Quality of Life; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Renal Replacement Therapy; Resistance Training; Restless Legs Syndrome; Vitamin E; Vitamins | 2016 |
3 trial(s) available for levodopa and ascorbic acid
| Article | Year |
|---|---|
An open trial of high-dosage antioxidants in early Parkinson's disease.
Topics: Adult; Aged; Ascorbic Acid; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Vitamin E | 1991 |
On-off effects in Parkinson's disease: a controlled investigation of ascorbic acid therapy.
Topics: Aged; Ascorbic Acid; Clinical Trials as Topic; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1983 |
Dissociating distractor-filtering at encoding and during maintenance.
Topics: Adult; Ascorbic Acid; Attention; Benserazide; Cell Phone; Control Groups; Double-Blind Method; Female; Humans; Levodopa; Male; Memory, Short-Term; Orientation; Pattern Recognition, Visual; Perceptual Masking; Placebo Effect; Reaction Time; Sensory Gating; Young Adult | 2014 |
69 other study(ies) available for levodopa and ascorbic acid
| Article | Year |
|---|---|
Identification of oxidation product of arbutin in mushroom tyrosinase assay system.
Topics: Agaricales; Arbutin; Catalysis; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Kinetics; Levodopa; Magnetic Resonance Spectroscopy; Mass Spectrometry; Monophenol Monooxygenase; Oxidation-Reduction; Oxygen Consumption; Polarography; Spectrophotometry, Ultraviolet | 2003 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Does conjugation of antioxidants improve their antioxidative/anti-inflammatory potential?
Topics: Acitretin; Animals; Anti-Inflammatory Agents; Antioxidants; Edema; Levodopa; Lipid Peroxidation; Rats; Spermine; Tretinoin | 2010 |
Letter: Ascorbic acid in levodopa therapy.
Topics: Ascorbic Acid; Drug Interactions; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1975 |
Colorimetric enzymatic determination of serum total carbon dioxide, as applied to the Vickers Multichannel 300 discrete analyzer.
Topics: Acetoacetates; Aminosalicylic Acids; Animals; Ascorbic Acid; Autoanalysis; Bilirubin; Carbon Dioxide; Carboxy-Lyases; Edible Grain; Humans; Hydrogen-Ion Concentration; Isoniazid; Levodopa; Malate Dehydrogenase; Methyldopa; Myocardium; Oxaloacetates; Phosphoenolpyruvate; Pyruvates; Sulfathiazoles; Swine | 1975 |
Dihydropteridine reductase deficiency associated with severe neurologic disease and mild hyperphenylalaninemia.
Topics: 5-Hydroxytryptophan; Ascorbic Acid; Consanguinity; Dopamine; Humans; Infant; Levodopa; Liver; Male; NADH, NADPH Oxidoreductases; Nervous System Diseases; Phenylalanine; Phenylalanine Hydroxylase; Phenylketonurias; Serotonin | 1979 |
[Adaptation to the Centrifichem of the estimation of blood sugar according to Trinder's method. Kinetic study of the main drug interferences (author's transl)].
Topics: Ascorbic Acid; Blood Glucose; Centrifugation; Gentisates; Kinetics; Levodopa; Methyldopa | 1978 |
Letter: Parkinson's disease and ascorbate.
Topics: Ascorbic Acid; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 1976 |
Ascorbate in the treatment of experimental transplanted melanoma.
Topics: Animals; Ascorbic Acid; Dehydroascorbic Acid; Female; Levodopa; Lung Neoplasms; Male; Malondialdehyde; Melanoma, Experimental; Mice; Neoplasm Transplantation | 1991 |
Effect of L-dopa, oxyferriscorbone and ferrous iron on in vivo lipid peroxidation.
Topics: 2,3-Diketogulonic Acid; Alloxan; Animals; Antioxidants; Ascorbic Acid; Drug Combinations; Ethane; Ferric Compounds; Iron; Levodopa; Linolenic Acids; Lipid Peroxidation; Male; Rats; Rats, Inbred Strains | 1991 |
Production of L-dopa by Aspergillus terreus.
Topics: Antioxidants; Ascorbic Acid; Aspergillus; Culture Media; Kinetics; Levodopa; Monophenol Monooxygenase; Substrate Specificity; Tyrosine | 1990 |
Stereoselective electron transfer between chiral substrates and metal chelates anchored to polypeptides.
Topics: Ascorbic Acid; Electrons; Epinephrine; Iron; Levodopa; Models, Molecular; Peptides; Polyglutamic Acid; Protein Conformation | 1989 |
An electrometric method for the determination of tyrosinase activity.
Topics: Ascorbic Acid; Catechol Oxidase; Hydrogen-Ion Concentration; Indolequinones; Indoles; Kinetics; Levodopa; Methods; Monophenol Monooxygenase; Oxidation-Reduction; Protons; Quinones; Spectrophotometry | 1985 |
Antagonization of the behavioral activation produced by direct stimulation of forebrain dopamine receptors caused by intraaccumbens injections of neurotensin.
Topics: Animals; Ascorbic Acid; Brain; Dopamine; Hydroxydopamines; Injections; Levodopa; Male; Motor Activity; Neurotensin; Norepinephrine; Nucleus Accumbens; Oxidopamine; Rats; Rats, Inbred Strains; Receptors, Dopamine; Septal Nuclei; Stereotyped Behavior | 1988 |
Interaction between specific dietary factors and experimental chemotherapy of metastatic melanoma.
Topics: Animals; Ascorbic Acid; Diet; Female; Levodopa; Lung Neoplasms; Melanoma; Mice; Mice, Inbred Strains; Phenylalanine; Tyrosine | 1986 |
Modulation of peroxidation in murine melanoma by dietary tyrosine-phenylalanine restriction, levodopa methylester chemotherapy, and sodium ascorbate supplementation.
Topics: Animals; Ascorbic Acid; Diet; Female; Levodopa; Lipid Peroxides; Liver; Malondialdehyde; Melanoma; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Phenylalanine; Tyrosine | 1985 |
[The determination of bilirubin as azobilirubin in plasma and serum with the Greiner electronic selective analyzer GSA II (author's transl)].
Topics: Ascorbic Acid; Azo Compounds; Bilirubin; Chemistry, Clinical; Diazonium Compounds; Epinephrine; Hemoglobins; Hemolysis; Histidine; Humans; Hyperlipidemias; Levodopa; Methyldopa; Norepinephrine; Rifampin; Spectrophotometry, Ultraviolet; Statistics as Topic; Tyrosine | 1974 |
Sodium ascorbate enhancement of carbidopa-levodopa methyl ester antitumor activity against pigmented B16 melanoma.
Topics: Animals; Antineoplastic Agents; Ascorbic Acid; Carbidopa; Cell Line; Diet; Drug Synergism; Drug Therapy, Combination; Female; Injections, Intraperitoneal; Levodopa; Melanoma; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Neoplasms, Experimental; Phenylalanine; Tyrosine | 1983 |
[Genetic improvement in Vicia faba and favism. I. Distribution and levels of presumably hemolytic metabolites].
Topics: Ascorbic Acid; Fabaceae; Favism; Glucosides; Hemolysin Proteins; Levodopa; Plants, Medicinal; Pyrimidinones; Seeds; Uracil; Uridine | 1981 |
Lipid peroxidation in brain: interactions of L-DOPA/dopamine with ascorbate and iron.
Topics: Animals; Ascorbic Acid; Brain; Dopamine; Iron; Levodopa; Lipid Peroxidation; Male; Mice | 1995 |
Antiparkinsonian therapies and brain mitochondrial complex I activity.
Topics: Animals; Antioxidants; Antiparkinson Agents; Antipsychotic Agents; Ascorbic Acid; Brain; Cholinergic Antagonists; Dopamine; Dose-Response Relationship, Drug; Levodopa; Male; Mitochondria; NAD(P)H Dehydrogenase (Quinone); Rats; Rats, Sprague-Dawley; Selegiline | 1995 |
[Preparation of a levodopa/carbidopa solution in ascorbic acid (citridopa) and chromatographic and electrochemical assessment of its stability over 24 hours].
Topics: Ascorbic Acid; Carbidopa; Chromatography, High Pressure Liquid; Drug Stability; Humans; Levodopa; Solutions; Time Factors | 1995 |
Impaired oxidation of pyruvate in human embryonic fibroblasts after exposure to L-dopa.
Topics: Ascorbic Acid; Cells, Cultured; Fetus; Fibroblasts; Humans; Levodopa; Mitochondria; Oxidation-Reduction; Oxidative Phosphorylation; Pyruvates; Pyruvic Acid; Radiation-Protective Agents; Succinates; Succinic Acid | 1994 |
L-dopa inhibits complex IV of the electron transport chain in catecholamine-rich human neuroblastoma NB69 cells.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Ascorbic Acid; Brain; Catecholamines; Electron Transport; Electron Transport Complex IV; Humans; Levodopa; NAD(P)H Dehydrogenase (Quinone); Neuroblastoma; Rats; Tumor Cells, Cultured | 1995 |
Formation of melanin pigment by a mutant of Bacillus thuringiensis H-14.
Topics: Amino Acids; Ascorbic Acid; Bacillus thuringiensis; Culture Media; Levodopa; Melanins; Mutagenesis; Spores, Bacterial; Tyrosine | 1993 |
Ascorbic acid protects against levodopa-induced neurotoxicity on a catecholamine-rich human neuroblastoma cell line.
Topics: Ascorbic Acid; Brain; Brain Neoplasms; Catecholamines; Cell Line; Drug Interactions; Female; Humans; Levodopa; Male; Neuroblastoma; Parkinson Disease; Quinones; Selegiline | 1993 |
Levodopa toxicity in foetal rat midbrain neurones in culture: modulation by ascorbic acid.
Topics: Animals; Ascorbic Acid; Cells, Cultured; Levodopa; Mesencephalon; Neurons; Rats | 1993 |
Levodopa stability in solution: time course, environmental effects, and practical recommendations for clinical use.
Topics: Antiparkinson Agents; Ascorbic Acid; Carbidopa; Drug Combinations; Drug Stability; Drug Storage; Humans; Levodopa; Light; Parkinson Disease; Temperature; Time Factors | 1996 |
Differential neurotoxicity induced by L-DOPA and dopamine in cultured striatal neurons.
Topics: Animals; Antiparkinson Agents; Ascorbic Acid; Cell Death; Cells, Cultured; Cellular Senescence; Corpus Striatum; Dopamine; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Levodopa; Neurons; Neurotoxins; Oxidation-Reduction; Rats; Rats, Wistar | 1996 |
Dopamine- and L-beta-3,4-dihydroxyphenylalanine hydrochloride (L-Dopa)-induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Y cells. Effects of oxidative stress and antioxidative factors.
Topics: Ascorbic Acid; Catalase; Cell Survival; Deferoxamine; Dopamine; Levodopa; Lipid Peroxidation; Neuroblastoma; Oxidative Stress; Superoxide Dismutase; Tumor Cells, Cultured; Vitamin E | 1997 |
Enhancing effect of manganese on L-DOPA-induced apoptosis in PC12 cells: role of oxidative stress.
Topics: Acetylcysteine; Animals; Antioxidants; Apoptosis; Ascorbic Acid; Cell Survival; Chromatography, High Pressure Liquid; Dopamine; Dopamine Agents; Drug Synergism; Flow Cytometry; Levodopa; Manganese Poisoning; Oxidative Stress; PC12 Cells; Rats | 1999 |
Antioxidants protect against dopamine-induced metallothionein-III (GIF) mRNA expression in mouse glial cell line (VR-2g).
Topics: Adrenergic Agents; Adrenergic alpha-Agonists; Animals; Antioxidants; Ascorbic Acid; Cell Line; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Glutathione; Glycerol-3-Phosphate Dehydrogenase (NAD+); Glycerolphosphate Dehydrogenase; Levodopa; Metallothionein; Mice; Neuroglia; Norepinephrine; Oxidopamine; Protein Isoforms; Receptors, Dopamine D1; Receptors, Dopamine D2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Vitamin E | 2000 |
L-DOPA production by immobilized tyrosinase.
Topics: Agaricales; Ascorbic Acid; Chitin; Diamines; Enzymes, Immobilized; Glutaral; Kinetics; Levodopa; Monophenol Monooxygenase; Tyrosine | 2000 |
Manganese increases L-DOPA auto-oxidation in the striatum of the freely moving rat: potential implications to L-DOPA long-term therapy of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; Animals; Ascorbic Acid; Chlorides; Chromatography, High Pressure Liquid; Corpus Striatum; Dialysis Solutions; Dopamine; Homovanillic Acid; Infusion Pumps; Levodopa; Male; Manganese; Manganese Compounds; Microdialysis; Movement; Oxidation-Reduction; Parkinson Disease; Rats; Rats, Wistar; Time Factors; Uric Acid | 2000 |
Effect of oxidative stress on stability and structure of neurofilament proteins.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Ascorbic Acid; Chlorides; Circular Dichroism; Dopamine; Electrophoresis, Polyacrylamide Gel; Ferric Compounds; Free Radicals; Levodopa; Molecular Weight; Neurofilament Proteins; Oxidation-Reduction; Oxidative Stress; Phosphorylation; Protein Structure, Secondary; Spectroscopy, Fourier Transform Infrared; Swine | 2000 |
Effect of alpha-methyldopa on pentoxyresorufin O-dealkylation in liver microsomes from rats treated with phenobarbital.
Topics: Animals; Ascorbic Acid; Cytochrome P-450 CYP2B1; Cytochrome P-450 CYP2E1 Inhibitors; Dopamine; Enzyme Inhibitors; Glutathione; Levodopa; Lipid Peroxidation; Male; Methyldopa; Microsomes, Liver; NADP; Oxazines; Phenobarbital; Rats; Rats, Wistar | 2001 |
L-DOPA and glia-conditioned medium have additive effects on tyrosine hydroxylase expression in human catecholamine-rich neuroblastoma NB69 cells.
Topics: Antioxidants; Apoptosis; Ascorbic Acid; bcl-X Protein; Buthionine Sulfoximine; Carbidopa; Cell Differentiation; Culture Media, Conditioned; Culture Media, Serum-Free; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Enzyme Inhibitors; Glutathione; Humans; Immunoblotting; Immunohistochemistry; In Situ Nick-End Labeling; Levodopa; Neuroblastoma; Neuroglia; Neurons; Proto-Oncogene Proteins c-bcl-2; Time Factors; Tumor Cells, Cultured; Tyrosine 3-Monooxygenase | 2001 |
Fullerene C60 and ascorbic acid protect cultured chromaffin cells against levodopa toxicity.
Topics: Animals; Antioxidants; Apoptosis; Ascorbic Acid; Chromaffin Cells; Dopamine Agents; Drug Interactions; Fullerenes; Immunohistochemistry; In Situ Nick-End Labeling; Levodopa; Oxidative Stress; Protective Agents; Rats; Rats, Wistar; Tyrosine 3-Monooxygenase | 2003 |
Kinobeon A as a potent tyrosinase inhibitor from cell culture of safflower: in vitro comparisons of kinobeon A with other putative inhibitors.
Topics: Agaricales; Alkenes; Arbutin; Ascorbic Acid; Carthamus tinctorius; Dose-Response Relationship, Drug; Humans; Inhibitory Concentration 50; Levodopa; Monophenol Monooxygenase; Peptides; Phytotherapy; Pyrones | 2003 |
Plasma and CSF markers of oxidative stress are increased in Parkinson's disease and influenced by antiparkinsonian medication.
Topics: Adult; alpha-Tocopherol; Antioxidants; Antiparkinson Agents; Ascorbic Acid; Biomarkers; Brain; Dopamine; Female; Humans; Levodopa; Lipoproteins; Male; Middle Aged; Oxidative Stress; Parkinson Disease; Reference Values; Sulfhydryl Compounds; Ubiquinone; Up-Regulation | 2004 |
Involvement of reactive oxygen species generated from melanin synthesis pathway in phytotoxicty of L-DOPA.
Topics: alpha-Tocopherol; Antioxidants; Ascorbic Acid; Daucus carota; Dopamine; Lactuca; Levodopa; Lipid Peroxidation; Melanins; Oxidative Stress; Plant Roots; Poaceae; Reactive Oxygen Species; Thiobarbituric Acid Reactive Substances; Time Factors | 2005 |
Microchip capillary electrophoresis with a cellulose-DNA-modified screen-printed electrode for the analysis of neurotransmitters.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Ascorbic Acid; Buffers; Cattle; Cellulose; DNA, Single-Stranded; Dopamine; Electrophoresis, Microchip; Levodopa; Microelectrodes; Neurotransmitter Agents; Norepinephrine | 2005 |
l-DOPA administration enhances 6-hydroxydopamine generation.
Topics: Animals; Antioxidants; Antiparkinson Agents; Ascorbic Acid; Corpus Striatum; Drug Interactions; Edetic Acid; Hydroxylation; Iron; Levodopa; Lipid Peroxidation; Male; Melatonin; Oxidopamine; Rats; Rats, Wistar | 2005 |
A spectroscopic study on applicability of spectral analysis for simultaneous quantification of l-dopa, benserazide and ascorbic acid in batch and flow systems.
Topics: Ascorbic Acid; Benserazide; Calibration; Levodopa; Reproducibility of Results; Spectrophotometry, Ultraviolet | 2005 |
Endogenous melatonin protects L-DOPA from autoxidation in the striatal extracellular compartment of the freely moving rat: potential implication for long-term L-DOPA therapy in Parkinson's disease.
Topics: Animals; Ascorbic Acid; Corpus Striatum; Dopamine; Levodopa; Light; Male; Melatonin; Microdialysis; Movement; Oxidation-Reduction; Parkinson Disease; Quinones; Rats; Rats, Wistar | 2006 |
Effect of oxidative stress induced by L-dopa on endogenous antioxidants in PC-12 cells.
Topics: alpha-Tocopherol; Animals; Antioxidants; Ascorbic Acid; Dopamine Agents; Drug Interactions; Levodopa; Oxidative Stress; PC12 Cells; Rats | 2006 |
Determination of L-dopa using electropolymerized 3,3',3'',3'''-tetraaminophthalocyanatonickel(II) film on glassy carbon electrode.
Topics: Ascorbic Acid; Carbon; Electrochemistry; Electrodes; Indoles; Isoindoles; Levodopa; Nickel; Polymers | 2007 |
Elevated dopamine levels during gestation produce region-specific decreases in neurogenesis and subtle deficits in neuronal numbers.
Topics: Analysis of Variance; Animals; Animals, Newborn; Antioxidants; Ascorbic Acid; Benzazepines; Brain; Bromodeoxyuridine; Cell Count; Cell Death; Cell Proliferation; Dopamine; Dopamine Agents; Embryo, Mammalian; Female; In Situ Nick-End Labeling; Levodopa; Mice; Neurons; Phosphopyruvate Hydratase; Pregnancy; Tyrosine 3-Monooxygenase | 2007 |
Melatonin inhibits 6-hydroxydopamine production in the brain to protect against experimental parkinsonism in rodents.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Ascorbic Acid; Brain; Central Nervous System Depressants; Chromatography, High Pressure Liquid; Dopamine; Dopamine Agents; Ferrous Compounds; Levodopa; Male; Melatonin; Mice; Mice, Inbred BALB C; Oxidopamine; Parkinsonian Disorders | 2009 |
L-Ascorbate, a strong inducer of L-dopa (3,4-dihydroxy-L-phenylalanine) production from pre-grown mycelia of Aspergillus oryzae NRRL-1560.
Topics: Ascorbic Acid; Aspergillus oryzae; Chromatography, High Pressure Liquid; Fuzzy Logic; Levodopa; Tyrosine | 2010 |
Bioconversion of L-tyrosine to L-DOPA by a novel bacterium Bacillus sp. JPJ.
Topics: Ascorbic Acid; Bacillus; Biotransformation; Copper Sulfate; Enzyme Assays; Hydrogen-Ion Concentration; Kinetics; Levodopa; Monophenol Monooxygenase; Phylogeny; Tyrosine | 2011 |
Purification and characterization of phenoloxidase from brine shrimp Artemia sinica.
Topics: Animals; Artemia; Ascorbic Acid; Benzoic Acid; Biocatalysis; Catechol Oxidase; Catechols; Citric Acid; Copper; Cysteine; Electrophoresis, Polyacrylamide Gel; Enzyme Assays; Enzyme Inhibitors; Hydrogen-Ion Concentration; Kinetics; Levodopa; Molecular Weight; Monophenol Monooxygenase; Phenylthiourea; Substrate Specificity; Sulfites; Temperature | 2011 |
Effects of zingerone [4-(4-hydroxy-3-methoxyphenyl)-2-butanone] and eugenol [2-methoxy-4-(2-propenyl)phenol] on the pathological progress in the 6-hydroxydopamine-induced Parkinson's disease mouse model.
Topics: Animals; Antioxidants; Ascorbic Acid; Catalase; Corpus Striatum; Disease Models, Animal; Dopamine; Eugenol; Free Radical Scavengers; Glutathione; Glutathione Peroxidase; Guaiacol; Levodopa; Male; Mice; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Superoxide Dismutase | 2011 |
Efficient microbial conversion of L-tyrosine to L-DOPA by Brevundimonas sp. SGJ.
Topics: Ascorbic Acid; Biotransformation; Caulobacteraceae; Cell Size; Copper Sulfate; Hydrogen-Ion Concentration; Levodopa; Monophenol Monooxygenase; Motion; Temperature; Time Factors; Tyrosine | 2012 |
Effect of L-ascorbic Acid on the climbing ability and protein levels in the brain of Drosophila model of Parkinson's disease.
Topics: Age Factors; alpha-Synuclein; Animals; Animals, Genetically Modified; Antioxidants; Antiparkinson Agents; Ascorbic Acid; Brain; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Drosophila; Drosophila Proteins; Gait Disorders, Neurologic; Humans; Levodopa; Membrane Proteins; Neurons; Parkinson Disease; Transcription Factors | 2012 |
Striatal interaction among dopamine, glutamate and ascorbate.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; Ascorbic Acid; Basal Ganglia Diseases; Chromatography, High Pressure Liquid; Dopamine; Dopamine Agents; Dopamine Antagonists; Electrochemistry; Fluorometry; Glutamic Acid; Haloperidol; Levodopa; Male; Microdialysis; Neostriatum; Rats; Rats, Sprague-Dawley | 2012 |
Polyphenol oxidase activity and antioxidant properties of Yomra apple (Malus communis L.) from Turkey.
Topics: Antioxidants; Ascorbic Acid; Biphenyl Compounds; Caffeic Acids; Catechin; Catechol Oxidase; Chlorogenic Acid; Coumaric Acids; Enzyme Inhibitors; Fruit; Kinetics; Levodopa; Malus; Oxidation-Reduction; Parabens; Phenylpropionates; Picrates; Plant Extracts; Plant Proteins; Polyphenols; Propionates; Quercetin; Sulfites | 2014 |
Behavioral impairments and serotonin reductions in rats after chronic L-dopa.
Topics: Affect; Animals; Antioxidants; Ascorbic Acid; Behavior, Animal; Biogenic Monoamines; Brain Chemistry; Cognition; Dopamine Agents; Fear; Levodopa; Male; Maze Learning; Prefrontal Cortex; Psychomotor Performance; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Antagonists | 2015 |
Effective L-Tyrosine Hydroxylation by Native and Immobilized Tyrosinase.
Topics: Agaricales; Air; Ascorbic Acid; Boron; Buffers; Diffusion; Enzyme Stability; Enzymes, Immobilized; Hydrogen-Ion Concentration; Hydroxylation; Levodopa; Monophenol Monooxygenase; Phosphates; Temperature; Tyrosine | 2016 |
Liquid levodopa-carbidopa in advanced Parkinson's disease with motor complications.
Topics: Aged; Antiparkinson Agents; Ascorbic Acid; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Kaplan-Meier Estimate; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Treatment Outcome | 2017 |
A comparative study of stabilising effect and antioxidant activity of different antioxidants on levodopa-loaded liposomes.
Topics: Antioxidants; Antiparkinson Agents; Ascorbic Acid; Curcumin; Dopamine Agents; Drug Liberation; Drug Stability; Levodopa; Lipid Bilayers; Liposomes; Superoxide Dismutase | 2018 |
3D cloves bud like Gd doped ZnO strewn rGO hybrid for highly selective determination of l-dopa in the presence of carbidopa and ascorbic acid.
Topics: Ascorbic Acid; Carbidopa; Equipment Design; Graphite; Humans; Hydrogen-Ion Concentration; Levodopa; Limit of Detection; Mucuna; Nanocomposites; Nanoparticles; Reproducibility of Results; Seeds; Urinalysis; X-Ray Diffraction; Zinc Oxide | 2019 |
Ascorbic acid can alleviate the degradation of levodopa and carbidopa induced by magnesium oxide.
Topics: Antiparkinson Agents; Ascorbic Acid; Carbidopa; Humans; Levodopa; Magnesium Oxide; Parkinson Disease | 2022 |
Novel liposomal formulations for protection and delivery of levodopa: Structure-properties correlation.
Topics: Ascorbic Acid; Drug Carriers; Humans; Levodopa; Liposomes; Parkinson Disease | 2023 |